הלוואות ואשראי לטווח ארוך של החברה: iTeos (ITOS)

iTeos Therapeutics (ITOS) generates revenue by developing anti-tumor agents, receiving payments and royalties from GSK for the joint implementation of antibodies. However, geopolitical conflicts and reagent shortages are slowing down drug certification. Meanwhile, the company strictly adheres to laboratory waste disposal regulations. This price chart confirms these data, where the debt load stands at 0.01, reflecting the current financial state of the business.

This indicator determines the long-term debt load, which is critical for assessing the issuer's solvency. The metric aggregates all liabilities with a maturity exceeding one year, revealing the resilience of the capital structure. By analyzing the long-term debt level of the company, an investor sees the real cost of borrowed financing. The stability of this figure confirms the financial discipline of iTeos Therapeutics (ITOS). This correlates with their strict adherence to ethical norms and ESG standards in onco-immunology.